ImmunityBio Shares Tumble Despite Record Revenue and Regulatory Progress

ImmunityBio's stock fell sharply amid a legal probe and insider selling, overshadowing 700% revenue growth for its cancer drug ANKTIVA and key FDA submission progress.

The biotechnology firm ImmunityBio finds itself in a curious position. While announcing explosive revenue growth and advancing the approval pathway for its key cancer drug, its stock experienced a sharp decline, shedding approximately 20% of its value last week. This divergence between strong operational performance and negative market sentiment highlights a complex investor landscape.

Legal Scrutiny and Insider Transactions Cast a Shadow

Two significant concerns appear to be weighing on investor confidence. First, regulatory law firm Pomerantz LLP has initiated an investigation into potential securities law violations by ImmunityBio. Second, and occurring almost simultaneously, company insider Barry J. Simon, a member of the board, disposed of 175,000 shares in late February, a transaction valued at nearly $1.8 million.

The market's reaction was pronounced. After trading above $10 per share the prior week, ImmunityBio's stock closed at $7.94. This sell-off occurred in spite of a series of fundamentally positive developments from the company.

ANKTIVA Drives Unprecedented Commercial Growth

The cornerstone of ImmunityBio's recent success is its cancer immunotherapy, ANKTIVA. The drug's commercial launch has yielded extraordinary financial results. For the 2025 fiscal year, revenue generated by ANKTIVA surged by roughly 700% to reach $113 million. This commercial traction contributed to a narrowing of the company's net loss, which improved to $351.4 million from $413.6 million in the previous year. ImmunityBio's financial position remains supported by a solid cash reserve of $242.8 million.

Regulatory Pathway Advances with FDA Submission

On the regulatory front, the company recently took a critical step by submitting a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for ANKTIVA. A favorable aspect of this submission is that the FDA requested additional data for its review but did not mandate new clinical trials. This regulatory feedback suggests a potentially more streamlined path toward a label expansion, saving considerable time and resources.

Further bolstering the drug's profile are compelling new clinical data. A recent study demonstrated that combining ANKTIVA with the standard BCG therapy achieved an 84% response rate in patients, a significant improvement over the 52% response rate observed with BCG alone. Based on these results, company management plans to file another regulatory application in the fourth quarter of 2026.

Global Commercial Footprint Expands

ImmunityBio is also making strides in international markets. The company secured conditional marketing authorization for its therapy in the European Union in February. New distribution partnerships established in Europe and Saudi Arabia are designed to accelerate commercialization efforts across the 33 countries where the drug is now approved.

Looking ahead, a key meeting with the FDA is scheduled for this month. The agenda will focus on the next steps for ImmunityBio's proprietary recombinant BCG program. This initiative aims to address the severe global supply shortage affecting the standard BCG treatment. The near-term trajectory of the stock will likely hinge on whether the company's continued operational progress can eventually overshadow the current legal and sentiment-related overhangs.